BioNTech (NASDAQ:BNTX) Given New $130.00 Price Target at HC Wainwright

Key Points

• HC Wainwright lowered its price target on BioNTech from $140 to $130 while maintaining a "buy" rating, a target that the firm says implies about a 52.49% upside from the current share price.
• Consensus among analysts is a "Moderate Buy" with an average target of $133.07; ratings breakdown: 1 Strong Buy, 12 Buy, 4 Hold and 1 Sell.
• Notable institutional moves include Dodge & Cox increasing its stake by 315.7% to 3,647,091 shares (~$359.7M) and GSK buying a new ~ $84.7M stake, with institutions owning about 15.52% of the stock.

BioNTech (NASDAQ:BNTX - Get Free Report) had its price target lowered by equities research analysts at HC Wainwright from $140.00 to $130.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price suggests a potential upside of 52.49% from the stock's current price.

Several other research analysts also recently commented on BNTX. Raymond James Financial reissued an "outperform" rating on shares of BioNTech in a report on Tuesday, March 10th. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, March 14th. Leerink Partners lowered BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 price objective for the company. in a research note on Monday, February 2nd. Berenberg Bank restated a "buy" rating on shares of BioNTech in a research report on Friday, January 23rd. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $171.00 target price on shares of BioNTech in a research note on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $133.07.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $85.25 on Tuesday. The company has a 50 day moving average of $103.23 and a 200 day moving average of $101.47. The stock has a market cap of $21.43 billion, a P/E ratio of -16.27 and a beta of 1.51. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01.

Institutional Trading of BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Dodge & Cox increased its stake in BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company's stock valued at $359,676,000 after acquiring an additional 2,769,654 shares during the last quarter. GSK plc bought a new stake in BioNTech during the fourth quarter worth about $84,711,000. BNP Paribas Financial Markets lifted its stake in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock worth $150,235,000 after purchasing an additional 474,796 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of BioNTech by 344.4% in the 3rd quarter. Bank of America Corp DE now owns 573,356 shares of the company's stock worth $56,544,000 after purchasing an additional 444,332 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of BioNTech during the 4th quarter valued at about $41,656,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.